Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Celgene-CELG -- Ignore unavailable to you. Want to Upgrade?

To: Rudy Saucillo who wrote (181)	12/1/1998 1:04:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 804

Rudy: What are the new (proposed?) rules at FDA/Congress for off-label promotion of approved drugs? Thanks for your post. Am trying to gather all of the CELG-relevant abstracts together. Rick

To: Rudy Saucillo who wrote (181)	12/1/1998 1:04:00 PM
From: Biomaven	Read Replies (2) \| Respond to of 804

Rudy, The url is getting contaminated by your closing parenthesis. Here's a cleaner version: biz.yahoo.com The key point here is that pretty much nothing works in these MM patients for long (note some of them have already had two bone marrow transplants). Incidence is around 13,000 a year, and median survival is around 2 years. Thus the current patient population must be around 25,000. My guess based on these early results is that most, if not all, of these will end up on Thalomid, and MM will become by far the biggest use for Thalomid. If I'm right, the stock is very cheap at these levels, although CELG will probably need one more trip to the financing well. I've bought some at around these levels a month or two back and more recently I added to my position. Peter